In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...
Read MoreMultiple Myeloma Posts on Medivizor
Comparing daratumumab with other treatment for multiple myeloma
In a nutshell This paper studied the effectiveness of daratumumab (Darzalex) in multiple myeloma patients who had received at least 1 previous treatment. This study concluded that daratumumab was more effective when used in combination with lenalidomide or bortezomib. Some background There is no standard treatment option for multiple myeloma that...
Read MoreCommon side effects of new treatments in multiple myeloma
In a nutshell This paper reviewed the adverse (negative) events associated with new treatments in multiple myeloma. Patients should be closely monitored for adverse events. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Treatment includes the use of various types of medications. Adverse events...
Read MoreElozutumab in relapsed or refractory multiple myeloma
In a nutshell This paper reviewed the effect of elozutumab (Empliciti) in the treatment of relapsed or refractory multiple myeloma. This study concluded that elozutumab with lenalidomide (Revlimid) and dexamethasone (Ozurdex) can be considered in relapsed or refractory multiple myeloma. Some background Multiple myeloma...
Read MoreRisk of adverse events in new versus conventional treatment for multiple myeloma
In a nutshell This paper studied the risk of adverse events in patients who receive treatment for multiple myeloma. The use of new drugs increased the risk of low blood count, peripheral neuropathy and blood clots. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Multiple myeloma can be treated with drugs...
Read MoreHeart-related complications in multiple myeloma treatment
In a nutshell This paper reviewed the risk of heart disease in patients receiving treatment for multiple myeloma. Reducing the risk of heart disease is important in patients with multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of blood. Treatment for multiple myeloma involves a group of drugs called proteasome...
Read More5 Things You Probably Didn’t Know About Your Adrenal Glands
The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...
Read MoreRight To Try: Needed Legislation or Snake Oil?
Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process. There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...
Read MoreWhat are the long-term outcomes after plerixafor and G-CSF before stem cell transplantation?
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read MoreDenosumab vs zoledronic acid for bone protection in multiple myeloma
In a nutshell This paper compared the effect of denosumab (Prolia) and zoledronic acid (Zometa) in patients with newly diagnosed multiple myeloma. Denosumab could be considered in patients with newly diagnosed multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of the blood. Multiple myeloma can cause bone...
Read MoreImproved survival with carfilzomib lenalidomide and dexamethasone
In a nutshell This paper compared the effect of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Ozurdex) to lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. The addition of carfilzomib was associated with a longer survival. Some background Multiple myeloma is a cancer of the...
Read MoreDaratumumab with bortezomib and dexamethasone in Japanese patients
In a nutshell This paper compared the safety and effectiveness of daratumumab (Darzalex) in combination with bortezomib (Velcade) and dexamethasone (Ozurdex) in patients with relapsed or refractory multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of the blood. Multiple myeloma can be refractory (not responding...
Read More
